These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21200360)

  • 1. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.
    Baxter R; Baine Y; Ensor K; Bianco V; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2011 Mar; 30(3):e41-8. PubMed ID: 21200360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.
    Memish ZA; Dbaibo G; Montellano M; Verghese VP; Jain H; Dubey AP; Bianco V; Van der Wielen M; Gatchalian S; Miller JM
    Pediatr Infect Dis J; 2011 Apr; 30(4):e56-62. PubMed ID: 21278617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.
    Nolan T; Richmond P; Marshall H; McVernon J; Alexander K; Mesaros N; Aris E; Miller J; Poolman J; Boutriau D
    Pediatr Infect Dis J; 2011 Mar; 30(3):190-6. PubMed ID: 20948453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
    Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.
    Knuf M; Kieninger-Baum D; Habermehl P; Muttonen P; Maurer H; Vink P; Poolman J; Boutriau D
    Vaccine; 2010 Jan; 28(3):744-53. PubMed ID: 19887137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial.
    Østergaard L; Silfverdal SA; Berglund J; Flodmark CE; West C; Bianco V; Baine Y; Miller JM
    Vaccine; 2012 Jan; 30(4):774-83. PubMed ID: 22107850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.
    Vesikari T; Karvonen A; Bianco V; Van der Wielen M; Miller J
    Vaccine; 2011 Jun; 29(25):4274-84. PubMed ID: 21443965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
    Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
    Østergaard L; Van der Wielen M; Bianco V; Miller JM
    Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.
    Bryant KA; Marshall GS
    Expert Rev Vaccines; 2011 Jul; 10(7):941-50. PubMed ID: 21806393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.